Fractyl Health (GUTS) Interest & Investment Income (2023 - 2026)
Fractyl Health's (GUTS) quarterly Interest & Investment Income came in at $593000.0 in Q1 2026, up 17.89% YoY from $503000.0 in Q1 2025, and down 8.06% on a QoQ basis from $645000.0 in Q4 2025.
Fractyl Health (GUTS) Interest & Investment Income (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Interest & Investment Income data on file, last reported at $593000.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 17.89% year-over-year to $593000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 54.1% YoY) and the FY2025 annual result came in at $1.5 million, down 62.86% from the prior year.
- Interest & Investment Income declined to $593000.0 in Q1 2026, from $645000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.4 million in Q2 2024 to a low of $154000.0 in Q2 2023.
- A 4-year average of $579923.1 and a median of $503000.0 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 792.86% — and 2025, when it tumbled 83.56%.
- Tracing GUTS's Interest & Investment Income over 4 years: stood at $463000.0 in 2023, then jumped by 56.8% to $726000.0 in 2024, then decreased by 11.16% to $645000.0 in 2025, then fell by 8.06% to $593000.0 in 2026.
- The last three Interest & Investment Income figures came in at $593000.0 (Q1 2026), $645000.0 (Q4 2025), and $166000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | 431,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 431,000.00 |
| Mar 31, 2026 | 593,000.00 |
| Dec 31, 2025 | 645,000.00 |
| Sep 30, 2025 | 166,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 503,000.00 |
| Dec 31, 2024 | 726,000.00 |
| Sep 30, 2024 | 947,000.00 |
| Jun 30, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 463,000.00 |
| Sep 30, 2023 | 226,000.00 |
| Jun 30, 2023 | 154,000.00 |
| Mar 31, 2023 | 417,000.00 |